Immuno-Oncology Alliances Command Big Deal Premiums

les Nouvelles - Journal of the Licensing Executives Society, Volume LIV No. 1, March 2019

5 Pages Posted: 24 Mar 2019

Date Written: January 16, 2019

Abstract

Everyone knows that immune-oncology (IO) is the hottest ticket in biopharma alliances. With almost 100 announced deals involving PD-1, and more than half as many with PD-L1, it seems that everyone is jumping onto the IO dancefloor. However, as with all things alliance-related, the devil is in the details. What IO molecular target(s) should one bring to the dance? CD20, HER1 or HER2, TNF-alpha, CTLA4… and the list goes on. And when is the optimal time to seek and strike a deal: preclinical data, Phase I safety data, Phase II clinical proof of concept, or Phase III pivotal trials as a monotherapy? In other words, with such a crowded dancefloor, when is the best time to join the IO dance?

Keywords: Immuno-Oncology, IO Dancefloor, CD20, HER1, HER2, TNF-Alpha, CTLA4, Monotherapy

Suggested Citation

Edwards, Mark Gearard, Immuno-Oncology Alliances Command Big Deal Premiums (January 16, 2019). les Nouvelles - Journal of the Licensing Executives Society, Volume LIV No. 1, March 2019, Available at SSRN: https://ssrn.com/abstract=3317049

Mark Gearard Edwards (Contact Author)

BioScience Advisors Inc. ( email )

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
27
Abstract Views
158
PlumX Metrics